The Modified Osseodensification Visco-Elastic (MOVE) Sinus Protocol: A Case Series to Illustrate the Combination of Osseodensification with Viscoelastic Bone Replacement Material.

INTRODUCTION: The Modified Osseodensification Visco-Elastic (MOVE) protocol combines two established techniques for sinus lifting: osseodensification drills to elevate the Schneiderian membrane, and the use of a viscoelastic putty to distribute forces on the membrane, a combination first described by Neiva et al. (2019). This case series elucidates the technique for combining these materials, and its possible benefits, which include reduced procedure time, less traumatic sinus elevation, and more versatility for unusual sinus anatomy, such as sloped sinus floors and immediate implant sites. CASE SERIES: The three cases, illustrating a single implant, adjacent implants, and an immediate implant, demonstrate various indications for using the MOVE protocol, documented with two- and three-dimensional radiography. The MOVE protocol is explained in detail with supplemental photos of the steps. CONCLUSION: Applying the MOVE protocol has the potential to allow for same-day implant placement in sites that previously required preoperative bone augmentation or lateral wall sinus access, thereby reducing the extent of surgical invasiveness associated with implant placement in the posterior maxilla.

Short-term impact of introducing a soft opt-out organ donation system in Wales: before and after study.

OBJECTIVES: To determine the short-term impact of a soft opt-out organ donation system on consent rates and donor numbers. DESIGN: Before and after observational study using bespoke routinely collected data. SETTING: National Health Service Blood and Transplant. PARTICIPANTS: 205 potential organ donor cases in Wales. INTERVENTIONS: The Act and implementation strategy. PRIMARY AND SECONDARY OUTCOMES: Consent rates at 18 months post implementation compared with 3 previous years, and organ donor numbers 21 months before and after implementation. Changes in organ donor register activity post implementation for 18 months. RESULTS: The consent rate for all modes of consent was 61.0% (125/205), showing a recovery from the dip to 45.8% in 2014/2015. 22.4% (46/205) were deemed consented donors: consent rate 60.8% (28/46). Compared with the 3 years before the switch there was a significant difference in Welsh consent rates (χ2 p value=0.009). Over the same time period, rest of the UK consent rates also significantly increased from 58.6% (5256/8969) to 63.1% (2913/4614) (χ2 p value<0.0001), therefore the Wales increase cannot be attributed to the Welsh legislation change. Deceased donors did not increase: 101 compared with 104. Organ donation registration increased from 34% to 38% with 6% registering to opt-out. CONCLUSION: This is the first rigorous initial evaluation with bespoke data collected on all cases. The longer-term impact on consent rates and donor numbers is unclear. Concerns about a potential backlash and mass opting out were not realised. The move to a soft opt-out system has not resulted in a step change in organ donation behaviour, but can be seen as the first step of a longer journey. Policymakers should not assume that soft opt-out systems by themselves simply need more time to have a meaningful effect. Ongoing interventions to further enhance implementation and the public's understanding of organ donation are needed to reach the 2020 target of 80% consent rates. Further longitudinal monitoring is required.

Incorporation of vitronectin into fibrin clots. Evidence for a binding interaction between vitronectin and gamma A/gamma' fibrinogen.

Vitronectin is an abundant plasma protein that regulates coagulation, fibrinolysis, complement activation, and cell adhesion. Recently, we demonstrated that plasma vitronectin inhibits fibrinolysis by mediating the interaction of type 1 plasminogen activator inhibitor with fibrin (Podor, T. J., Peterson, C. B., Lawrence, D. A., Stefansson, S., Shaughnessy, S. G., Foulon, D. M., Butcher, M., and Weitz, J. I. (2000) J. Biol. Chem. 275, 19788-19794). The current studies were undertaken to further examine the interactions between vitronectin and fibrin(ogen). Comparison of vitronectin levels in plasma with those in serum indicates that approximately 20% of plasma vitronectin is incorporated into the clot. When the time course of biotinylated-vitronectin incorporation into clots formed from (125)I-fibrinogen is monitored, vitronectin incorporation into the clot parallels that of fibrinogen in the absence or presence of activated factor XIII. Vitronectin binds specifically to fibrin matrices with an estimated K(d) of approximately 0.6 microm. Additional vitronectin subunits are assembled on fibrin-bound vitronectin multimers through self-association. Confocal microscopy of fibrin clots reveals the globular vitronectin aggregates anchored at intervals along the fibrin fibrils. This periodicity raised the possibility that vitronectin interacts with the gamma A/gamma' variant of fibrin(ogen) that represents about 10% of total fibrinogen. In support of this concept, the vitronectin which contaminates fibrinogen preparations co-purifies with the gamma A/gamma' fibrinogen fraction, and clots formed from gamma A/gamma' fibrinogen preferentially bind vitronectin. These studies reveal that vitronectin associates with fibrin during coagulation, and may thereby modulate hemostasis and inflammation.